Development of a core outcome set for clinical trials in inflammatory bowel disease: Study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Ma, Christopher ^a   Panaccione, Remo ^a   Fedorak, Richard N ^b   Parker, Claire E ^c   Khanna, Reena ^c,d   Levesque, Barrett G ^c,e   Sandborn, William J ^c,e   Feagan, Brian G ^c,d   Jairath, Vipul ^c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

consensus methods; core outcome set; Crohn's disease; Delphi; Inflammatory bowel disease; systematic review; ulcerative colitis

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DELPHI STUDY; DRUG INDUSTRY; HEALTH CARE; HUMAN; INFLAMMATORY BOWEL DISEASE; OUTCOME ASSESSMENT; SCIENTIST; SEMI STRUCTURED INTERVIEW; SYSTEMATIC REVIEW; CONSENSUS DEVELOPMENT; INTERVIEW; LITERATURE; METHODOLOGY; PROCEDURES; STAKEHOLDER ENGAGEMENT;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DELPHI TECHNIQUE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERVIEWS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; STAKEHOLDER PARTICIPATION;

EID: 85020685032     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-016146     Document Type: Article

References (42)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
2. Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
3. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 2016;13:13-27.
4. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-72.
5. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
6. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324-38.
7. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
8. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-265e1-265.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
10. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
13. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
14. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
15. Khanna R, Jairath V, Vande Casteele N, et al. Efficient early drug development for ulcerative colitis. Gastroenterology 2016;150:1056-60.
16. Jairath V, Levesque BG, Vande Casteele N, et al. Evolving concepts in phases I and II drug development for Crohn's disease. J Crohns Colitis 2017;11.
17. Hindryckx P, Baert F, Hart A, et al. Clinical trials in luminal Crohn's disease: a historical perspective. J Crohns Colitis 2014;8:1339-50.
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
20. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56.
21. Targownik LE, Sexton KA, Bernstein MT, et al. The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease. Am J Gastroenterol 2015;110:1001-12.
22. Gracie DJ, Williams CJ, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol 2016;111:541-51.
23. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016;14:1385-1397e10-1397.
24. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13:132.
25. D'Haens G, Feagan B, Colombel JF, et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012;143:1461-9.
26. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: omeract filter 2.0. J Clin Epidemiol 2014;67:745-53.
27. Chiarotto A, Terwee CB, Deyo RA, et al. A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set. Trials 2014;15:511.
28. Egan AM, Smith V, Devane D, et al. Effectiveness of prepregnancy care for women with pregestational diabetes mellitus: protocol for a systematic review of the literature and identification of a core outcomes set using a Delphi survey. Trials 2015;16:356.
29. Harman NL, Bruce IA, Callery P, et al. MOMENT-management of otitis media with effusion in cleft palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials 2013;14:70.
30. Iyengar S, Williamson PR, Schmitt J, et al. Development of a core outcome set for clinical trials in Rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials 2016;17:429.
31. Kelly LE, Jansson LM, Moulsdale W, et al. A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey. Trials 2016;17:536.
32. MacLennan S, Bekema HJ, Williamson PR, et al. A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey. Trials 2015;16:76.
33. Tong A, Manns B, Hemmelgarn B, et al. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials 2015;16:364.
34. Gargon E. The COMET (Core Outcome Measures in Effectiveness trials) Initiative. Maturitas 2016;91:91-2.
35. Kirkham JJ, Gorst S, Altman DG, et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials 2015;16:373.
36. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med 2011;8:e1000393. 37. The ICHOM Standard Set for Inflammatory Bowel Disease [Available from: http://www.ichom.org/medical-conditions/inflammatory-bowel-disease/2016.
37. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
38. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22.
39. Kuper A, Reeves S, Levinson W. An introduction to reading and appraising qualitative research. BMJ 2008;337:a288.
40. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400.
41. Hirsch M, Duffy JM, Barker C, et al. Protocol for developing, disseminating and implementing a core outcome set for endometriosis. BMJ Open 2016;6:e013998.
42. Amiot A, Peyrin-Biroulet L, Current P-BL. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol 2015;8:66-82.